EIT Health supported start-up extends seed investment round to €4.8 million to unlock the power of cough monitoring

Portuguese C-mo Medical Solutions, one of the winners of the EIT Health Headstart programme in 2020, announced an extension to its seed investment round. The round now totals €4.8 million and with the addition of Novalis Biotech as a new investor. Novalis is joining the seed investment round led by Boehringer Ingelheim Venture Fund and participation.

C-mo Medical Solutions is an award-winning digital health start-up that develops solutions for the diagnosis and management of cough-incident medical conditions. The company’s mission is to unravel the clinical potential of cough assessment and solve the major unmet medical needs associated with the management of chronic cough.

As Diogo Tecelão, co-founder and CEO of the company explains, the unique technology that stands behind the solution analyses the subtle characteristics of the patient’s cough, translating them into actionable insights that add significant value in several key use cases. C-mo has the potential to greatly speed-up diagnosis, optimise treatment courses, improve disease management, and support pharmaceutical research.

In 2020 the company was among 15 winners of the EIT Health Headstart programme, receiving €50,000, mentoring, business support and access to the health innovation ecosystem via EIT Health’s vast network. Now, with the new funding, the Portuguese innovators want to bring its cough-monitoring tech to the market.

This is yet another example of a success story that proves EIT Health’s support to be an important stage in a start-up growth journey, providing entrepreneurs with the necessary skills and connections to move onto the next level.